4-[4-[[[3-(methanesulfonamido)phenyl]carbamoylamino]methyl]-2-methylphenoxy]-N-methylpyridine-2-carboxamide

• 分子结构分类: 有机化合物 - 有机氧化合物
• 英文名称: 4-[4-[[[3-(methanesulfonamido)phenyl]carbamoylamino]methyl]-2-methylphenoxy]-N-methylpyridine-2-carboxamide
• 化学式: C₂₃H₂₅N₅O₅S
• 分子量: 483.5
• InChiKey: ZYRPLKUTVLWDAR-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  1.8
• 重原子数：
  34
• 可旋转键数：
  8
• 环数：
  3.0
• sp3杂化的碳原子比例：
  0.17
• 拓扑面积：
  147
• 氢给体数：
  4
• 氢受体数：
  7

文献信息

• DDR2 INHIBITORS FOR THE TREATMENT OF OSTEOARTHRITIS
  申请人：Merck Patent GmbH

  公开号：US20150225369A1

  公开（公告）日：2015-08-13

  The present invention relates to compounds of the formula I and in particular medicaments comprising at least one compound of the formula I for use in the treatment and/or prophylaxis of physiological and/or pathophysiological states in the triggering of which DDR2 is involved, in particular for use in the treatment and/or prophylaxis of osteoarthritis, hepatocirrhosis, traumatic cartilage injuries, pain, allodynia or hyperalgesia.

  本发明涉及公式I的化合物，特别是包含至少一种公式I化合物的药物，用于治疗和/或预防生理和/或病理状态，其中触发DDR2参与，特别是用于治疗和/或预防骨关节炎、肝硬化、创伤性软骨损伤、疼痛、触痛或过敏性疼痛。
• NOVEL AZABENZIMIDAZOLE TETRAHYDROPYRAN DERIVATIVES
  申请人：Merck Sharp & Dohme Corp.

  公开号：EP2888006A1

  公开（公告）日：2015-07-01
• [EN] NOVEL AZABENZIMIDAZOLE TETRAHYDROPYRAN DERIVATIVES<br/>[FR] NOUVEAUX DÉRIVÉS D'AZABENZIMIDAZOLE TÉTRAHYDROPYRANE
  申请人：MERCK SHARP & DOHME

  公开号：WO2014031465A1

  公开（公告）日：2014-02-27

  Novel compounds of the structural formula (I) are activators of AMP-protein kinase and may be useful in the treatment, prevention and suppression of diseases mediated by the AMPKactivated protein kinase. The compounds of the present invention may be useful in the treatment of Type 2 diabetes, hyperglycemia, metabolic syndrome, obesity, hypercholesterolemia, and hypertension.
• [EN] DDR2 INHIBITORS FOR THE TREATMENT OF OSTEOARTHRITIS<br/>[FR] INHIBITEURS DE DDR2 POUR LE TRAITEMENT DE L'ARTHROSE
  申请人：MERCK PATENT GMBH

  公开号：WO2014032755A2

  公开（公告）日：2014-03-06

  The present invention relates to compounds of the formula (I) and in particular medicaments comprising at least one compound of the formula (I) for use in the treatment and/or prophylaxis of physiological and/or pathophysiological states in the triggering of which DDR2 is involved, in particular for use in the treatment and/or prophylaxis of osteoarthritis, hepatocirrhosis, traumatic cartilage injuries, pain, allodynia or hyperalgesia.